Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Nicotinamide wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Probably helps
2 of 3 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (1)
Outcomes where both Afamelanotide and Nicotinamide have evidence — compare verdict strength side-by-side.
Approved EPP regimen is a single 16 mg controlled-release SUBCUTANEOUS IMPLANT inserted by a clinician approximately every 60 days. There is NO consumer dose — afamelanotide is a prescription drug administered in a clinical setting, not a self-dosed supplement.
any
16 mg subcutaneous controlled-release implant (prescription, clinician-administered)
500mg twice daily
Morning and evening with meals
Niacinamide tablets (500mg)
Over each ~60-day implant cycle
Days to weeks
8-24 weeks
Around implant placement
3-12 months
8 weeks
Days
First days
Afamelanotide for Erythropoietic Protoporphyria.
N Engl J Med (2015) · Rct · n=168
Two multicenter, randomized, double-blind, placebo-controlled Phase 3 trials of 16 mg subcutaneous afamelanotide implants every 60 days (EU n=74, US n=94)
Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial.
JAMA Dermatol (2015) · Rct · n=55
Randomized multicenter trial in non-segmental vitiligo: combination 16 mg afamelanotide + NB-UV-B (n=28) vs NB-UV-B monotherapy (n=27)
Afamelanotide: A Review in Erythropoietic Protoporphyria.
Am J Clin Dermatol (2016) · Review
Drug review summarizing the approved 16 mg controlled-release subcutaneous implant for EPP
A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention.
The New England journal of medicine (2015) · Rct · n=386
ONTRAC: phase-3, double-blind RCT randomizing 386 patients with ≥2 prior non-melanoma skin cancers to 500 mg nicotinamide twice daily or placebo for 12 months
Skin Cancer Prevention and Antiaging: Role of Nicotinamide.
International journal of molecular sciences (2026) · Review
Review of the biological rationale and clinical evidence for nicotinamide and NAD+ precursors in photoaging and cutaneous carcinogenesis
Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris.
International journal of dermatology (1995) · Rct · n=76
Double-blind RCT of 76 patients randomized to 4% nicotinamide gel or 1% clindamycin gel twice daily for 8 weeks for moderate inflammatory acne
The ONTRAC RCT used 500 mg twice daily (1000 mg/day total) and reduced new non-melanoma skin cancers by 23%. Effect requires continuous use; it disappeared after discontinuation. Curve is indicative — only the 1000 mg/day regimen is directly RCT-supported.
AI-estimated from published studies. Interpret as directional guidance.
Nicotinamide has a higher evidence score (5.5/10 vs 5/10) and wins in 2 of 3 categories.
No known interactions between Afamelanotide and Nicotinamide have been documented in our database. However, always consult a healthcare provider before combining supplements.